Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C33H33NO3 |
| Molecular Weight | 491.62 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 1 / 1 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CC#C[C@@H](CC(O)=O)C1=CC=C(OCC2=CC=C(CN3CCC4(CC3)C=CC5=C4C=CC=C5)C=C2)C=C1
InChI
InChIKey=FHRWHNJJQGSCQC-LJAQVGFWSA-N
InChI=1S/C33H33NO3/c1-2-5-29(22-32(35)36)27-12-14-30(15-13-27)37-24-26-10-8-25(9-11-26)23-34-20-18-33(19-21-34)17-16-28-6-3-4-7-31(28)33/h3-4,6-17,29H,18-24H2,1H3,(H,35,36)/t29-/m0/s1
| Molecular Formula | C33H33NO3 |
| Molecular Weight | 491.62 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 1 / 1 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
Approval Year
| Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 11:53:48 GMT 2023
by
admin
on
Sat Dec 16 11:53:48 GMT 2023
|
| Record UNII |
LAD0ZG7FFO
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Code | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Code | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
DB15046
Created by
admin on Sat Dec 16 11:53:48 GMT 2023 , Edited by admin on Sat Dec 16 11:53:48 GMT 2023
|
PRIMARY | |||
|
CHEMBL3545086
Created by
admin on Sat Dec 16 11:53:48 GMT 2023 , Edited by admin on Sat Dec 16 11:53:48 GMT 2023
|
PRIMARY | |||
|
1292290-38-0
Created by
admin on Sat Dec 16 11:53:48 GMT 2023 , Edited by admin on Sat Dec 16 11:53:48 GMT 2023
|
PRIMARY | |||
|
LAD0ZG7FFO
Created by
admin on Sat Dec 16 11:53:48 GMT 2023 , Edited by admin on Sat Dec 16 11:53:48 GMT 2023
|
PRIMARY | |||
|
51049992
Created by
admin on Sat Dec 16 11:53:48 GMT 2023 , Edited by admin on Sat Dec 16 11:53:48 GMT 2023
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
TARGET -> AGONIST |
BINDING
Ki
|
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
ACTIVE MOIETY |
Official Title: Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Escalating Oral Doses of LY2881835 in Healthy Subjects and Patients With Type 2 Diabetes Mellitus
Purpose: This will be the first study in which LY2881835 is given to humans in order to evaluate the safety and any side effects of LY2881835 in humans as well as how long LY2881835 stays in the body and its effect on blood sugar levels.
The study consists of two parts. In part A, healthy subjects will participate and in part B, patients with type 2 Diabetes Mellitus (T2DM) will participate.
|
